This study also showed that patients who received non-intensive salvage therapy regimens (LDAC-based or hypomethylating agents) had less proliferating FLT3-ITD-mutated AML with more frequent features common to leukemia seen in older patients (e.g., secondary AML, IDH mutations) [29,30,31]. The gene discussed is IDH1; the disease is leukemia.